

## Special Issue

# Current Advances in the Development of SARS-CoV-2 Vaccines

### Message from the Guest Editors

The ongoing SARS-CoV-2 pandemic has highlighted the need for rapid development, testing, distribution, and analysis of additional coronavirus vaccines. We are publishing this special issue to address these and many additional remaining questions for this pandemic. The appearance of multiple novel variants that exhibit the capacity to cause enhanced spread, pathogenesis, and/or evade prior immunological protection, with the added contribution of a strong potential for the emergence of additional novel variants, make it clear that additional vaccination and therapeutic efforts will be needed to resolve this pandemic. This special issue calls for submissions for manuscripts regarding many aspects of vaccines for SARS-CoV-2, including but not limited to: ☒ Duration of immunity ☒ Correlates of immunity ☒ Mechanisms of immunity ☒ Animal model development for testing SARS-CoV-2 vaccines ☒ Novel vaccines ☒ Adjuvants to improve vaccination ☒ Improvements in manufacturing and distribution of vaccines ☒ Optimal timing, routes or dosing of vaccinations

---

### Guest Editors

Dr. Steven B. Bradfute

Center for Global Health, Division of Infectious Diseases, Department of Internal Medicine, University of New Mexico, Albuquerque, NM 505, USA

Dr. Scott Anthony

National Institute of Allergy and Infectious Diseases (NIAID), Frederick, MD, USA

---

### Deadline for manuscript submissions

closed (15 September 2021)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/77177](https://mdpi.com/si/77177)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).